Raphael Deferiere - 02 Jun 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Accounting Officer
Signature: /s/ Gregory Weinhoff, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 02 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:26:38 UTC
Previous filing: 03 Jun 2025
Next filing: 03 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Deferiere Raphael	Chief Accounting Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM	/s/ Gregory Weinhoff, attorney-in-fact	03 Jun 2025	0002071320

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Share Option (right to buy)	Award	$0	+165,000		$0.000000	165,000	02 Jun 2025	Ordinary Shares	165,000	$13.41	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to such option shall vest and become exercisable on June 2, 2026 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F2	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.